AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06547021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A light electrical current with zero frequency (tDCS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks.
Study NCT06547021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma Transcranial Alternating Current Stimulation (tACS)
Description: A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks.
Study NCT06547021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Transcranial Alternating Current Stimulation (tACS)
Description: A light electrical current with personalized theta frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks.
Study NCT06547021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham stimulation (i.e. only slight stimulation at the beginning and at the end for a few seconds with majority of the time having no stimulation) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks.
Study NCT06681415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution
Description: Adding albumin to the priming solution can help reduce hemodilution and consequent extracardiac complications by maintaining colloid oncotic pressure. Albumin helps counteract the intravascular fluid shift to the extravascular space and reduces the risk of complications associated with fluid imbalance.~Postoperative pulmonary complications following CPB can significantly impact postoperative outcomes. Patients developing PPC have prolonged mechanical ventilation, extended hospitalisation, longer ICU stays, and elevated postoperative mortality. One of the most common PPCs following CPB is pleural effusion.~Our primary objective was to evaluate the effectiveness of adding 100 ml of 20% human albumin to the CPB priming solution compared to standard priming, with a specific focus on its potential role in reducing the occurrence of pleural effusion.
Study NCT06681597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry ketone
Description: Human consumed 500mg of raspberry ketone
Study NCT05249790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recommended treatment schedule
Description: Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
Study NCT05249790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Treatment regimens different from the recommended one according to family physician personal practice
Study NCT06238362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPAP
Description: Algorithm for modification of CPAP therapy where pressure is reduced during the inspiratory phase though much of the expiratory phase, then is returned to full pressure near the end of the expiratory phase. Note that the same device that delivers CPAP can also deliver TPAP
Study NCT06238362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Gold standard for treating sleep apnea.
Study NCT06679790 — intervention group
Intervention type: OTHER
Intervention: None interventional
Description: Observational study
Study NCT06680947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 610
Description: Subcutaneously injection.
Study NCT06680947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously injection.
Study NCT05360966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-15512 Ophthalmic Solution
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Study NCT05360966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Study NCT03672760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioBreathApp
Description: Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
Study NCT03672760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IMT PowerBreath
Description: Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
Study NCT03672760 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IMT PowerBreath Placebo
Description: Inspiratory Muscle Training (IMT) without load
Study NCT05160025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual reality bicycling
Description: This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
Study NCT06241456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as an IV infusion at planned dose levels.
Study NCT06630143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Virtual and Clinical Simulation
Description: Participants will complete a preeclampsia case scenario through virtual simulation first and then engage in a clinical simulation involving the same case. This sequential intervention is designed to reinforce knowledge and skills.
Study NCT06630143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual simulation
Description: Participants will complete the preeclampsia case scenario using the vSim® platform, allowing them to engage in virtual clinical decision-making.
Study NCT06241456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as an IV infusion at planned dose levels.
Study NCT06680245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: Patients needing Ahmed valve implants to control intraocular pressures will be eligible. Eligible patients who consent will be randomized to receive either mitomycin-C or no intervention during implant surgery. Screening visits occur one week before surgery to assess eligibility and take baseline measurements (visual acuity, IOP, anterior chamber reaction). On surgery day, patients register at SJHH King Campus and undergo randomization. IOP is measured using a tonopen in the OR. An experienced glaucoma specialist performs the surgery, injecting 0.2 mg/ml mitomycin-C into the sclera for the experimental group, while the control group receives no intervention. The area is irrigated with 40mL balanced salt solution before implant insertion. Post-operative care includes topical antibiotics and steroids for six weeks, with follow-ups at 1 and 2 weeks, and 1, 3, 6, and 12 months to monitor visual acuity, IOP, anterior chamber reaction, complications, and additional glaucoma medications.
Study NCT04840147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JointRep®
Description: JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.
Study NCT04840147 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microfracture
Description: Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
Study NCT04840147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
Study NCT06241456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as an IV infusion at planned dose levels.
Study NCT06241456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered as an IV infusion at planned dose levels.
Study NCT06707454 — intervention group
Intervention type: DEVICE
Intervention: Digital Electroencephalography (DEEG)
Description: The enrolled patients will undergo Digital Electroencephalography (DEEG) monitoring for at least two hours. A senior epileptologist will make a DEEG interpretation to detect DEEG abnormality. DEEG patterns will be categorized according to the American Clinical Neurophysiology Society's standardized critical care DEEG terminology(normal, slowing and asymmetry, sharp and wave, periodic discharges, ictal patterns burst suppression, and electrocerebral silence)
Study NCT06707376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Kangaroo Mother Care
Description: * Initiation of KMC within 24 hours of birth.~* Continuous skin-to-skin contact for at least 8 hours per day, with gradual increase based on infant tolerance.~* Support for exclusive breastfeeding or expressed breast milk feeding.~* Ongoing assessment and support from trained neonatal nurses and lactation consultants.
Study NCT05120791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vegetable bouillon
Description: 14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
Study NCT05120791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: microalgae phaeodactylum
Description: 14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
Study NCT05120791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)
Description: 14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
Study NCT05120791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A combination of the vegetable bouillon, the microalgae and the beta-Glucan
Description: 14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
Study NCT06004583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical blood analysis
Description: Serum CRP and albumin levels
Study NCT05546398 — intervention group
Intervention type: DRUG
Intervention: Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab
Description: No study drug was administered during this study.
Study NCT05546398 — intervention group
Intervention type: OTHER
Intervention: No study drug
Description: No study drug was administered during this study.
Study NCT05151861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete removal of pharmacological treatment
Description: Removal of treatment
Study NCT05151861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Maintenance of pharmacological treatment
Study NCT06710782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Patients underwent intra-articular hyaluronic acid injection.
Study NCT06401850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Group
Description: The intervention provided to the training group focuses on improving skills to cope with polycystic ovary syndrome. This intervention includes topics such as encouraging healthy lifestyle habits, raising awareness about nutrition and exercise, teaching stress management techniques, and offering strategies to support hormonal balance. It provides participants with the tools they need to understand and manage symptoms that impact their lives. It also provides a supportive environment, encouraging participants to share their experiences with each other and receive support. This intervention aims to improve individuals' overall quality of life while strengthening their ability to manage their own health and well-being.
Study NCT06401850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: No intervention was made to the control group. This group did not receive additional training or support to cope with polycystic ovary syndrome. In this way, the effects of the control group on lifestyle, symptom management and overall quality of life were evaluated in comparison with the training group. This approach focuses on determining the direct effects of the intervention, while allowing to observe the natural course of the control group, and the results help to provide a clear assessment of the effectiveness of the intervention.
Study NCT06522672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: My Happy Flo
Description: The intervention aims to alleviate period symptoms including heavy flows, prolonged periods, cramps, mood disturbances, energy levels, cycle regulation, and fatigue. Blood tests for Vitamin D and Iron levels will be conducted at Baseline and after the third menstrual cycle. Participants will complete validated questionnaires assessing period symptoms after each menstrual cycle.
Study NCT06256302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverses Abdominis Plane Block
Description: Transverses abdominis plane block will be provided randomly using prospective double-blinding.
Study NCT06256302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltration
Description: Local wound infiltration will be provided randomly using prospective double-blinding.
Study NCT06477939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of L-TC
Description: Administration of L-TC (300 mg) as an IV perfusion, before each radiotion session~Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days.
Study NCT06477939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus Temozolomide
Description: Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days.
Study NCT06309043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
Description: a single dose，250 mg/m2
Study NCT06309043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
Description: a single dose，250 mg/m2
Study NCT06710782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous pulsed radiofrequency
Description: Patients underwent transcutaneous pulsed radiofrequency application plus genicular nerve block.
Study NCT06709066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mivacurium chloride
Description: mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion
Study NCT05192512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2928 injection
Description: TQB2928 injection is a CD47 Blocker.
Study NCT05274789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
Study NCT05274789 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
Study NCT04610684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 5-6 mg/mL/min AUC will be delivered over 30 - 60 minutes intravenously on Day 1 of each 21 day Cycle after completion of atezolizumab. For 4 cycles.
Study NCT04610684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 80-100 mg/m2 will be delivered over 60 minutes intravenously on Days 1-3 of each 21 day Cycle after completion of carboplatin (Day 1 only). For 4 cycles.
Study NCT04610684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be delivered over 60 (± 15) minutes intravenously on Day 1 of each 21 day Cycle for 4 cycles then continue as monotherapy maintenance with the same schedule.
Study NCT04773002 — intervention group
Intervention type: OTHER
Intervention: Different anesthesia methods
Description: Total intravenous anesthesia (TIVA)and volatile anesthesia
Study NCT06709066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: succinylcholine
Description: succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion)
Study NCT06708663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX009+IN10018
Description: The 7.5 mg/kg dose group will first enroll 3 to 6 subjects, and if the 7.5 mg/kg dose group is tolerable, then 3 to 6 subjects will continue to be enrolled into the 10 mg/kg dose group; if the 7.5 mg/kg dose group is not tolerable, a decision will be made to add a new, lower dose group after discussion between the sponsor and the investigator; in addition, based on the available study data, the sponsor and the investigator will discuss and decide whether to add an unplanned dose group or an exploratory group and decide on the appropriate recommended dose (RP2D) for the Phase IIa study.~IN10018 is fixed dose at 100mg daily.
Study NCT06710470 — intervention group
Intervention type: DRUG
Intervention: Deucravacitinib
Description: As per product label
Study NCT06710470 — intervention group
Intervention type: DRUG
Intervention: Systemic psoriasis medications
Description: As per product label
Study NCT06710470 — intervention group
Intervention type: OTHER
Intervention: No systemic medications
Description: Participants not exposed to any systemic medications
Study NCT06707597 — intervention group
Intervention type: OTHER
Intervention: Patient Interaction Group
Description: No interventions or procedures will be applied to the patients. To evaluate whether the pain, anxiety, and comfort of patients undergoing the same surgical procedure are influenced by each other, the average scale scores of patients in double and single rooms will be compared.
Study NCT06710847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4418959
Description: GSK4418959 will be administered.
Study NCT06710847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: PD-1 inhibitor will be administered.
Study NCT06708936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KSD-201
Description: Patients will receive approximately 5x10\^6 cells/dose DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
Study NCT06705907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Achieving Independence and Mastery in School (AIMS)
Description: Intervention targeting academic executive functioning
Study NCT06705907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Building Essential Social Skills for Teens (BESST)
Description: Intervention targeting social skills
Study NCT06708416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1110
Description: ONO-1110 tablets once a day
Study NCT06708416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study NCT06710223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: Toll-like receptor 9 (TLR9) agonist
Study NCT06710223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryoablation of liver
Study NCT06710223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Anti-CTLA4
Study NCT06710223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PDL1